Abivax (ABVX) Total Non-Current Liabilities: 2022-2025
- Abivax's Total Non-Current Liabilities fell 25.17% to $62.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was $62.9 million, marking a year-over-year decrease of 25.17%. This contributed to the annual value of $75.5 million for FY2024, which is 73.86% up from last year.
- Latest data reveals that Abivax reported Total Non-Current Liabilities of $62.9 million as of Q2 2025, which was down 11.79% from $71.3 million recorded in Q1 2025.
- In the past 5 years, Abivax's Total Non-Current Liabilities registered a high of $84.1 million during Q2 2024, and its lowest value of $17.2 million during Q4 2022.
- Its 3-year average for Total Non-Current Liabilities is $67.4 million, with a median of $71.3 million in 2025.
- Per our database at Business Quant, Abivax's Total Non-Current Liabilities skyrocketed by 151.96% in 2023 and then declined by 25.17% in 2025.
- Over the past 4 years, Abivax's Total Non-Current Liabilities (Quarterly) stood at $17.2 million in 2022, then surged by 151.96% to $43.4 million in 2023, then soared by 73.86% to $75.5 million in 2024, then declined by 25.17% to $62.9 million in 2025.
- Its Total Non-Current Liabilities was $62.9 million in Q2 2025, compared to $71.3 million in Q1 2025 and $75.5 million in Q4 2024.
